Recent developments in our profession, including antibody drug conjugates notably Trastuzumab Deruxtecan, a monoclonal antibody in HER2 low illness, have significantly altered our perception of breast cancer. We previously classified breast cancer as triple-negative, HER2-positive, and ER positive. Now the HER2 low has eliminated the old barrier and put them into the non-HER2 low category, which is really exciting.
Read The Full Transcript and Watch The Video Here
The data is really encouraging. In addition to the most recent FDA clearance of Sacituzumab Govitecan for the treatment of HR-positive, HER2-negative cancers. Additionally provides more choices for home-receptor-positive patients who have to transition to chemotherapy. They now have other choices. I believe the greatest difficulty or future difficulty will be determining how to sequence the agents.